April 2026
Retatrutide Phase 3 readout expected Q4 2026
Eli Lilly's triple-agonist retatrutide is on track for FDA submission late 2026 based on TRIUMPH Phase 3 results expected in Q4. Trial data so far suggests ~24% weight loss at top dose.
GLP-1 News & Updates: What\'s New in 2026
Pipeline drug approvals, pricing changes, FDA actions, and the latest GLP-1 weight-loss drug news.
Recent Headlines
March 2026
Orforglipron FDA submission accepted
Lilly's once-daily oral GLP-1 has FDA submission accepted with expected 2026 approval. First non-peptide oral GLP-1 with no food restrictions.
February 2026
CagriSema Phase 3 results show 22.7% weight loss
Novo Nordisk's cagrilintide+semaglutide combination matches tirzepatide in head-to-head trial. FDA submission expected 2026.
January 2026
Wegovy demand stabilizing as supply expands
Novo Nordisk reported normalized supply across all dose strengths as of late 2025. Compounded sema demand continues but slowing as branded availability improves.
December 2025
Compounded GLP-1 legal challenges continue
Ongoing court battles between FDA and compounding industry over which compounders can continue producing GLP-1s. Reputable telehealth providers using semaglutide salt forms or personalized doses to maintain compliance.
November 2025
Semaglutide for Alzheimer's — EVOKE results pending
Phase 3 EVOKE and EVOKE+ trials of semaglutide in early Alzheimer's disease continue enrollment with results expected 2026.
News Sections
- FDA Tracker — drug approvals, indication expansions, regulatory actions
- Policy & Pricing — Medicare/Medicaid coverage, executive actions, manufacturer pricing
- Celebrity GLP-1 — public figures using GLP-1 medications
Frequently Asked Questions
When will retatrutide be available?
Eli Lilly expects FDA approval in 2026 based on Phase 3 trial completion. Currently investigational only.
When will orforglipron be available?
FDA submission accepted in 2025; approval expected 2026. First non-peptide oral GLP-1.
Are GLP-1 prices coming down?
Some downward pressure: LillyDirect Zepbound vials at $349/mo, expanded patient assistance programs, and growing competition in compounded space. Branded list prices have been more resistant.